Online citations, reference lists, and bibliographies.
← Back to Search

The Dawning Era Of Polymer Therapeutics

R. Duncan
Published 2003 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
As we enter the twenty-first century, research at the interface of polymer chemistry and the biomedical sciences has given rise to the first nano-sized (5–100 nm) polymer-based pharmaceuticals, the 'polymer therapeutics'. Polymer therapeutics include rationally designed macromolecular drugs, polymer–drug and polymer–protein conjugates, polymeric micelles containing covalently bound drug, and polyplexes for DNA delivery. The successful clinical application of polymer–protein conjugates, and promising clinical results arising from trials with polymer–anticancer-drug conjugates, bode well for the future design and development of the ever more sophisticated bio-nanotechnologies that are needed to realize the full potential of the post-genomic age.
This paper references
10.1023/A:1007587523543
Anionic PAMAM Dendrimers Rapidly Cross Adult Rat Intestine In Vitro: A Potential Oral Delivery System?
R. Wiwattanapatapee (2004)
10.1038/bjc.1994.363
Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma.
L. Seymour (1994)
Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger.
J. Wu (1998)
10.1002/jgm.187
Different behavior of branched and linear polyethylenimine for gene delivery in vitro and in vivo
L. Wightman (2001)
Pharmacokinetic considerations for design and development
R. Duncan (1994)
10.1054/bjoc.2001.2026
PDEPT: polymer-directed enzyme prodrug therapy
R. Satchi (2001)
Antitumor effect of in vivo somatostatin receptor subtype 2 gene transfer in primary and metastatic pancreatic cancer models.
F. Vernejoul (2002)
10.1177/088391159200700205
Biocompatibility of Biopolymers
I. Volfová (1992)
10.1023/A:1014212630566
Intracellular Processing of Poly(Ethylene Imine)/Ribozyme Complexes Can Be Observed in Living Cells by Using Confocal Laser Scanning Microscopy and Inhibitor Experiments
T. Merdan (2004)
Delivery of therapeutics
Jain (1998)
Polyethylenimine
Boussif (1995)
The role of polymer conjugates in the diagnosis and treatment of cancer
R. Duncan (1996)
Characterization and anticancer activity of the micelle-forming polymeric anticancer drug adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer.
M. Yokoyama (1990)
Its antitumour activities in several model systems of human and murine tumours
Ochi (2001)
10.1038/nrc905
Clinical translation of angiogenesis inhibitors
R. Kerbel (2002)
10.1016/S0168-3659(01)00341-8
Development of the polymer micelle carrier system for doxorubicin.
T. Nakanishi (2001)
10.1212/WNL.45.7.1268
Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis
K. Johnson (1995)
10.1016/0014-3057(73)90063-3
Poly[N-(2-hydroxypropyl)methacrylamide]—I. Radical polymerization and copolymerization
J. Kopeček (1973)
10.1038/nrd988
The emerging field of nanotube biotechnology
C. Martin (2003)
Use of peginterferon α-2a (40KD) (Pegasys®) for the treatment of hepatitis
K. R. Reddy (2002)
10.1200/JCO.2004.12.043
Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
P. Sabbatini (2004)
Enhanced therapeutic effect and X-ray image
K. Iwai (1984)
10.1089/AID.1997.13.875
Anti-HIV type 1 activity of sulfated derivatives of dextrin against primary viral isolates of HIV type 1 in lymphocytes and monocyte-derived macrophages.
C. Javan (1997)
10.1038/11717
Therapeutic antibody fragments with prolonged in vivo half-lives
A. P. Chapman (1999)
Neocarzinostatin : the past, present, and future of an anticancer drug
前田 浩 (1997)
10.1016/S0168-3659(01)00328-5
Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic.
R. Duncan (2001)
design, activity and mechanism of action
Kopecek (2000)
10.1016/S0168-3659(99)00282-5
Neocarzinostatin: The past, present, and future of an anticancer drug
W. Shen (2000)
Metabolism of poly-l-glutamic acid (PG) paclitaxel (CT-2103); characterization of metabolites generated through proteolysis by lysosomal cathepsin B
S. Shaffer (2002)
10.1038/nrc903
Ligand-targeted therapeutics in anticancer therapy
T. Allen (2002)
Tumor irradiation enhances the tumor-specific distribution of poly(L-glutamic acid)-conjugated paclitaxel and its antitumor efficacy.
Chun Xing Li (2000)
A potential oral delivery system
Wiwattanapatapee (2000)
Phase I and pharmacological study of CT-2103, a poly(L-glutamic acid)–paclitaxel conjugate
Sludden (2001)
10.2165/00003088-199427040-00004
Polymer Conjugates
R. Duncan (1994)
10.1002/(SICI)1521-3935(19981101)199:11<2565::AID-MACP2565>3.0.CO;2-G
A novel modification of poly(L-lysine) leading to a soluble cationic polymer with reduced toxicity and with potential as a transfection agent
P. Ferruti (1998)
The sequestration of bile acids, a non-absorbed method for cholesterol reduction. A review
W. Mandeville (1997)
10.1080/10601329608014916
Dendrimers and Hyperbranched Polymers: Two Families of Three-Dimensional Macromolecules with Similar but Clearly Distinct Properties
J. M. J. Fréchet (1996)
10.1002/1521-3927(20020401)23:5/6<332::AID-MARC332>3.0.CO;2-I
Poly(amido‐amine)s: Biomedical Applications
P. Ferruti (2002)
Structural and biological characterisation of pegylated recombinant interferon α-2b and its therapeutic implications
Wang (2002)
mechanism of tumouritropic accumulation of proteins and the antitumour agent SMANCS
Y. Matsumura (1986)
10.1038/NM0698-655
The next frontier of molecular medicine: Delivery of therapeutics
R. Jain (1998)
10.1016/S0169-409X(02)00023-6
Mono-N-terminal poly(ethylene glycol)-protein conjugates.
O. Kinstler (2002)
10.1016/S0169-409X(96)00404-8
Biocompatibility of biomaterials: hemocompatibility, immunocompatiblity and biocompatibility of solid polymeric materials and soluble targetable polymeric carriers
B. Říhová (1996)
10.1038/sj.gt.3301351
Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application
R. Kircheis (2001)
Dendrimers and Other Dendritic Polymers (eds Frechet
P.R.L. Malenfant (2001)
Comparisons of the hyperbranched architecture with the perfect linear analogue
S. E. Stiriba (2002)
HPMA copolymer–TNP-470 conjugate
Satchi-Fainaro (2002)
Tumour irradiation enhances the tumour-specific distribution of poly(L-glutamic acid)–conjugated paclitaxel and its antitumour efficacy
C Li (2000)
Optimisation of CT 2106 : a water soluble polyLglutamic acid ( PG ) – camptothecin conjugate with enhanced in vivo antitumor efficacy
E. V. Batrakova (2001)
Biodegradable, elastic, shapememory polymers for potential biomedical applications
A. Lendlein (2002)
Stabilisation of substances in the circulation
C. Monfardini (1998)
10.1016/0014-5793(93)81177-2
Polysialic acids: potential in drug delivery
G. Gregoriadis (1993)
10.1002/jmri.10025
Micro‐MR angiography of normal and intratumoral vessels in mice using dedicated intravascular MR contrast agents with high generation of polyamidoamine dendrimer core: Reference to pharmacokinetic properties of dendrimer‐based MR contrast agents
H. Kobayashi (2001)
10.1006/MTHE.2001.0509
Overcoming the nuclear barrier: cell cycle independent nonviral gene transfer with linear polyethylenimine or electroporation.
S. Brunner (2002)
10.1016/S0168-3659(01)00281-4
New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties.
T. Etrych (2001)
Self-assembling complexes for gene delivery : from laboratory to clinical trial
A. Kabanov (1998)
Immunological problems of polymerbound drugs
B. Rihova (1985)
a phase I study of PK1 in patients with solid tumours
Thomson (1999)
Pegylated interferon α2 b treatment for patients with solid tumors : a phase I / II study
C. De Duve (2002)
10.1002/0470845821
Dendrimers and Other Dendritic Polymers: Frechet/Dendrimers
J. Fréchet (2001)
10.1021/BC970184F
Stabilization of substances in circulation.
C. Monfardini (1998)
10.1016/0168-3659(93)90172-2
Block copolymer micelles as vehicles for drug delivery
Kataoka Kazunori (1993)
10.1016/S1359-6349(03)90308-9
275 Phase 2 study of CT-2103 in patients with colorectal cancer having recurrent disease after treatment with a 4-fluorouracil-containing regimen
C. Redfern (2003)
10.1177/088391158600100109
Review: Advances in Intraperitoneal (Intracavitary) Administration of Synthetic Polymers for Immunotherapy and Chemotherapy
W. Regelson (1986)
10.1002/JBM.820211106
Effect of molecular weight (Mw) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats.
L. Seymour (1987)
a water soluble poly-L-glutamic acid (PG)–camptothecin conjugate with enhanced in vivo antitumor efficacy
De Vries (2001)
Use of peginterferon α2 a ( 40 KD ) ( Pegasys ® ) for the treatment of hepatitis C
Y.-S. Wang (2002)
Polymer therapeutics of angiogenesis inhibitors : HPMA copolymer – TNP470 conjugate
R. Satchi-Fainaro (2002)
10.1038/nrd984
Therapeutic antibodies for human diseases at the dawn of the twenty-first century
O. H. Brekke (2003)
10.1177/089686089401402S02
Icodextrin in Peritoneal Dialysis: Early Development and Clinical Use
C. Mistry (1994)
10.1016/0168-3659(90)90127-F
The clinical efficacy of poly(ethylene glycol)-modified proteins
Friedericka Fuertges (1990)
10.1038/sj.bjc.6600516
A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin
N. Schoemaker (2002)
10.1002/MACP.1985.020091985103
Immunogenicity of N-(2-hydroxypropyl) methacrylamide copolymers
B. Říhová (1985)
10.1016/S0022-3476(88)80271-3
Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase.
Y. Levy (1988)
10.1073/PNAS.98.3.1200
Polymer-based gene delivery with low cytotoxicity by a unique balance of side-chain termini.
D. Putnam (2001)
10.1002/ANIE.198103051
Polymeric Antitumor Agents on a Molecular and on a Cellular Level
L. Gros (1981)
Modulation of enhanced vascular permeability in tumours by a bradykinin antagonist, a cyclooxygenase inhibitor
J. Wu (1998)
10.3109/07357908609039825
The routinization of intraperitoneal (intracavitary) chemotherapy and immunotherapy.
W. Regelson (1986)
10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3
Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors.
M. Mammen (1998)
10.1016/0304-4165(86)90120-0
Fate of N-(2-hydroxypropyl)methacrylamide copolymers with pendent galactosamine residues after intravenous administration to rats.
R. Duncan (1986)
Poly [ N( hydroxypropyl ) methacrylamide ] . I . Radical polymerisation and copolymerisation
L. Sprincl (1973)
Enhanced antitumour activity of a new polymer linked DACH–platinum complex
J. R. Rice (2002)
HPMA copolymer–doxorubicin (PK1)
R. Duncan (1998)
Fundamentals of Polymer Science 2nd edn (CRC
P. C. Painter (1997)
10.1016/S0169-409X(02)00027-3
Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications.
Y. Wang (2002)
Drug delivery and targeting.
R. Langer (1998)
10.1016/S0939-6411(00)00075-8
HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action.
J. Kopeček (2000)
10.1002/JBM.820100612
New types of synthetic infusion solutions. III. Elimination and retention of poly-[N-(2-hydroxypropyl)methacrylamide] in a test organism.
L. Šprincl (1976)
A comprehensive review describing the many polymers that have been used to synthesize polymer–drug conjugates
S. Brocchini (1999)
A novel formulation for an insoluble but active agent
Denis (2000)
10.1016/S0959-8049(99)00030-1
HPMA copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo.
E. Gianasi (1999)
10.1016/S0169-409X(97)00109-9
Gene transfer with lipospermines and polyethylenimines.
Demeneix (1998)
10.1016/0006-2952(74)90174-9
Commentary. Lysosomotropic agents.
C. de Duve (1974)
10.1021/JA953729U
Polyacrylamides Bearing Pendant α-Sialoside Groups Strongly Inhibit Agglutination of Erythrocytes by Influenza Virus: The Strong Inhibition Reflects Enhanced Binding through Cooperative Polyvalent Interactions
G. Sigal (1996)
10.1034/J.1399-3011.2001.00921.X
Synthesis, isolation and characterization of Plasmodium falciparum antigenic tetrabranched peptide dendrimers obtained by thiazolidine linkages.
F. Chaves (2001)
The uses and properties of PEG-linked proteins.
C. Delgado (1992)
10.3109/10611869608996824
Polyethylene glycol modification: relevance of improved methodology to tumour targeting.
G. E. Francis (1996)
10.1016/S0169-409X(02)00022-4
Chemistry for peptide and protein PEGylation.
M. Roberts (2002)
10.1038/sj.gt.3301923
Gene Therapy Progress and Prospects: Nonviral vectors
T. Niidome (2002)
10.1177/088391159100600205
Review : Synthetic Polymers with Intrinsic Anticancer Activity
L. Seymour (1991)
Clinical translation of angiogenic inhibitors
R. Kerbel (2002)
Copaxone in experimental allergic encephalomyelitis and animal model for CMLS
M.S.D. Teitlebaum (1997)
novel potential intravaginal virucide
Stafford (1997)
10.1021/JA026835M
Hyperbranched molecular nanocapsules: comparison of the hyperbranched architecture with the perfect linear analogue.
Salah-Eddine Stiriba (2002)
10.1200/JCO.20.6.1668
Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin.
L. Seymour (2002)
10.1016/S1461-5347(98)00086-8
Polyethylene glycol-conjugated pharmaceutical proteins
P. Bailon (1998)
Poly(ethyleneglycol) multiblock copolymer as a carrier of anticancer drug doxorubicin
M. Pechar (2000)
10.1038/nrd1033
Effect of pegylation on pharmaceuticals
J. Harris (2003)
10.1016/S0169-409X(02)00021-2
The origin of pegnology.
F. F. Davis (2002)
Immunological problems of polymer-bound drugs.
B. Říhová (1985)
10.1016/S0168-3659(98)00124-2
Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine.
P. Julyan (1999)
Effect of molecular weight (Mω) of N-(2-hydroxypropyl) methacrylamide copolymers on body distributions and rate of excretion after subcutaneous, intraperitoneal and intravenous administration to rats
Seymour (1987)
10.1351/pac197646020103
Biologically Active Synthetic Polymers
D. S. Breslow (1976)
10.1016/0142-9612(85)90037-7
Stability in rat plasma and serum of lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl) methacrylamide copolymers.
P. Rejmanová (1985)
10.1016/S0169-409X(02)00028-5
Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C.
K. Rajender Reddy (2002)
10.1016/S0169-409X(02)00024-8
Enzymatic procedure for site-specific pegylation of proteins.
H. Sato (2002)
10.1021/LA001779T
Polycationic graft copolymers as carriers for oligonucleotide delivery. Complexes of oligonucleotides with polycationic graft copolymers.
H. Dautzenberg (2001)
10.1038/SJ.GT.3301946
Adverse effects of gene therapy: Gene therapy can cause leukaemia: no shock, mild horror but a probe
M. E. Gore (2003)
Polymer-directed enzyme prodrug therapy.
J. Cassidy (2000)
10.1136/mp.55.3.207-b
Self-assembling Complexes for Gene Delivery
A. Parker (2002)
10.1146/ANNUREV.BI.51.070182.002531
Carbohydrate-specific receptors of the liver.
G. Ashwell (1982)
Haemocompatibility, immunocompatibility and biocompatibility of solid polymeric materials and soluble targetable polymeric carriers
Rihova (1996)
Polymer conjugates : Pharmacokinetic considerations for design and development
Y. Matsumura (1994)
10.1128/AAC.43.10.2528
Anti-Kaposi’s Sarcoma and Antiangiogenic Activities of Sulfated Dextrins
M. Thornton (1999)
10.1021/BC000064Z
Drug delivery systems employing 1,6-elimination: releasable poly(ethylene glycol) conjugates of proteins.
Stanford Lee (2001)
[Phase II study].
H. Niitani (1995)
10.1016/0079-6700(75)90002-7
Synthetic biologically active polymers
L. G. Donaruma (1975)
Radical polymerisation and copolymerisation
J. Kopecek (1973)
Comparison of vascular permeability and enzymatic activation of the polymeric prodrug HPMA copolymer–doxorubicin (PK1) in human tumour xenografts
Sat (1999)
Star and Hyperbranched Polymers
S. Kobayashi (1999)
Carbohydrate recognition systems of the liver
G. Ashwell (1982)
Stability in plasma and serum of lysosomally degradable oligopeptide sequences in N-(2hydroxypropyl) methacrylamide copolymers
P Rejmanova (1985)
Copaxone disease progression
Johnson (1995)
10.1097/00001813-199206000-00001
Drug-polymer conjugates: potential for improved chemotherapy.
R. Duncan (1992)
10.1016/S0168-3659(99)00236-9
Molecular engineering of proteins and polymers for targeting and intracellular delivery of therapeutics.
P. Stayton (2000)
10.1021/BC990092L
Poly(ethylene glycol) multiblock copolymer as a carrier of anti-cancer drug doxorubicin.
M. Pechar (2000)
Dendrimers and other dendritic polymers
J. Fréchet (2001)
10.1016/0277-5379(91)91369-T
Preclinical evaluation of polymer-bound doxorubicin
R. Duncan (1991)
10.1016/0169-409X(91)90037-D
The therapeutic value of poly(ethylene glycol)-modified proteins
M. Nucci (1991)
Preliminary clinical study of the distribution of HPMA copolymer–doxorubicin bearing galactosamine
Julyan (1999)
Peptamin (glycyl-L-leucyl-mescaline) bound to blood plasma expander (polyvinylpyrrolidone) as a new depot form of a biologically active primary amine (mescaline)
H. Jatzkewitz (1955)
10.1126/SCIENCE.294.5547.1638
Safer and Virus-Free?
D. Ferber (2001)
DE - 310 , a novel macromolecular carrier for the camptothecin analogue DX8951 f [ II ] : Its antitumour activities in several model systems of human and murine tumours
P. De Vries (2001)
10.1080/1061186021000072456
HPMA Copolymers Platinates Containing Dicarboxylato Ligands. Preparation, Characterisation and In Vitro and In Vivo Evaluation
E. Gianasi (2002)
Anthracycline antibiotics noncovalently incorporated into block copolymer micelles : in vivo evaluation of anticancer activity
V. Alakhov (1996)
RenaGel®, a nonabsorbed calciumand phosphate-free phosphate binder, lowers serum phosphorus and parathyroid hormone
Slatopolsky (1999)
potential in drug delivery
Gregoriadis (1993)
10.1016/S0959-8049(02)80747-X
Pharmacological study of CT-2103 (XyotaxTM), a poly(L-glutamic acid)-paclitaxel conjugate administered every 3 weeks or every 2 weeks in a phase I study
R. Todd (2001)
Basic principles for design and transfer from the laboratory to the clinic
Duncan R. et al. Polymer–drug conjugates (2001)
10.1016/S0169-409X(00)00131-9
Delivery of molecular and cellular medicine to solid tumors.
R. Jain (2001)
An Experimental Study in the Rat
A. Alwmark (1986)
10.1002/CHIN.199503293
Synthesis and Antigenic Properties of Sialic Acid Based Dendrimers.
R. Roy (1995)
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.
Y. Matsumura (1986)
10.1038/nrd822
Preclinical safety evaluation of biotechnology-derived pharmaceuticals
J. Cavagnaro (2002)
10.1016/S1367-5931(02)00400-3
Biological applications of dendrimers.
M. Cloninger (2002)
10.1038/bjc.1996.587
Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: in vivo evaluation of anti-cancer activity.
E. Batrakova (1996)
Lysosomotropic agents
C De Duve (1974)
A Phase I study of PEG – camptothecin ( PEG – CPT ) in patients with advanced solid tumours : A novel formulation for an insoluble but active agent
R. B. Greenwald (2000)
Phase I Clinical and Pharmacokinetic Study of PK1 [N-(2-Hydroxypropyl)methacrylamide Copolymer Doxorubicin]: First Member of a New Class of Chemotherapeutic Agents—Drug-Polymer Conjugates
P. Vasey (1999)
10.1097/00042560-199703010-00003
A placebo-controlled, double-blind prospective study in healthy female volunteers of dextrin sulphate gel: a novel potential intravaginal virucide.
M. Stafford (1997)
10.1200/JCO.2002.02.051
Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study.
R. Bukowski (2002)
Polymers containing enzymatically degradable bonds
R Duncan (1984)
Metabolism of poly-L-glutamic acid (PG)–paclitaxel (CT-2103); proteolysis by lysosomal cathepsin B and identification of intermediate metabolites
Shaffer (2002)
10.1021/BC020091K
PDEPT: polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-beta-lactamase and HPMA copolymer-C-Dox as a model combination.
R. Satchi-Fainaro (2003)
10.1016/S0959-437X(00)00164-7
Drug-targeting strategies in cancer therapy.
P. Huang (2001)
10.1016/0142-9612(89)90075-6
Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing adriamycin. Immunogenicity, and effect on haematopoietic stem cells in bone marrow in vivo and mouse splenocytes and human peripheral blood lymphocytes in vitro.
B. Říhová (1989)
Special issue : Peptide and protein PEGylation
F. M. Veronese (2002)
Gene therapy. Safer and virus-free?
D. Ferber (2001)
10.1016/S1359-6446(02)02595-3
Fulfilling the promise: drug discovery in the post-genomic era.
S. Chanda (2003)
10.1073/PNAS.92.16.7297
A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine.
O. Boussif (1995)
10.1295/POLYMJ.17.117
A New Class of Polymers: Starburst-Dendritic Macromolecules
D. Tomalia (1985)
10.1016/0168-3659(90)90139-K
Polymer micelles as novel drug carrier: Adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer
Y. Masayuki (1990)
Preliminary report of a phase I study of escalating dose PG – paclitaxel ( CT2103 ) and fixed dose cisplatin in patients with solid tumors Proc
J. Schulz (2002)
Relevance to improved methodology to tumour targeting
Francis (1996)
10.1126/SCIENCE.1066102
Biodegradable, Elastic Shape-Memory Polymers for Potential Biomedical Applications
A. Lendlein (2002)
10.1021/BC0255900
Tat-conjugated synthetic macromolecules facilitate cytoplasmic drug delivery to human ovarian carcinoma cells.
A. Nori (2003)
10.1128/JVI.75.16.7621-7628.2001
Induction of Potent Human Immunodeficiency Virus Type 1-Specific T-Cell-Restricted Immunity by Genetically Modified Dendritic Cells
J. Lisziewicz (2001)
10.1007/3-540-12796-8_10
Soluble synthetic polymers as potential drug carriers
R. Duncan (1984)
Immunogenicity of N( 2hydroxypropyl ) methacrylamide copolymers
B. Rihova
Biomedical applications Macromol
P. Ferruti (2002)
A phase I/II study of PG–paclitaxel (CT2103) in patients (pts) with recurrent ovarian, fallopian tube, or peritoneal cancer
P Sabbatini (2002)
Preliminary report of a phase I study of escalating dose PG–paclitaxel (CT-2103) and fixed dose cisplatin in patients with solid tumors
Kudelka (2002)
10.1007/978-4-431-68349-0_27
Targeting Chemotherapy of Hepatocellular Carcinoma
T. Konno (1987)
10.1097/00001813-200411000-00011
Handbook of Anticancer Drug Development
D. Budman (2003)
10.1007/978-4-431-66914-2_12
Metamorphosis of Neocarzinostatin to SMANCS: Chemistry, Biology, Pharmacology, and Clinical Effect of the First Prototype Anticancer Polymer Therapeutic
H. Maeda (1997)
10.1038/sj.bjc.6690657
Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours
A. Thomson (1999)
10.1016/S0169-409X(02)00180-1
Effective drug delivery by PEGylated drug conjugates.
R. Greenwald (2003)
10.1007/PL00000576
Copolymer 1: from basic research to clinical application
D. Teitelbaum (1997)
10.1007/BF00687318
Reduced cardiotoxicity of doxorubicin given in the form ofN-(2-hydroxypropyl) methacrylamide conjugates: an experimental study in the rat
T. Yeung (2004)
Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate.
Chun Xing Li (1998)
10.1046/J.1523-1755.1999.00240.X
RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group.
E. Slatopolsky (1999)
10.1016/0959-8049(94)00514-6
Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier.
L. Seymour (1995)
10.1038/NBT0490-343
Site-Directed Pegylation of Recombinant Interleukin-2 at its Glycosylation Site
R. Goodson (1990)
10.1038/nrd989
The further evolution of biotech
T. Nagle (2003)
Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image.
K. Iwai (1984)
10.1002/ANIE.200390108
A chemical adaptor system designed to link a tumor-targeting device with a prodrug and an enzymatic trigger.
A. Gopin (2003)
10.1007/BFB0119259
Recent developments in the rational design of multivalent glycoconjugates
R. Roy (1997)
10.1097/00001813-200104000-00003
Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel
J. M. Meerum Terwogt (2001)
10.1515/ZNB-1955-0106
An ein kolloidales Blutplasma-Ersatzmittel (Polyvinylpyrrolidon) gebundenes Peptamin (Glycyl-L-leucyl-mezcalin) als neuartige Depotform für biologisch aktive primäre Amine (Mezcalin)
H. Jatzkewitz (1955)
Early development and clinical use
C. D. Mistry (1994)
10.1097/00002030-199804000-00009
Reduction of the viral load of HIV‐1 after the intraperitoneal administration of dextrin 2‐sulphate in patients with AIDS
S. Shaunak (1998)
Poly ( amidoamine ) s : Biomedical applications Macromol
P. Ferruti (2002)
PEGASPARAGINASE : a review of clinical studies
O. Kinstler
potential for improved chemotherapy
Duncan (1992)
Peptide and protein PEGylation
F. M. Veronese (2002)
Fundamentals of Polymer Science
P. Painter (1994)
10.1021/MA0108867
Pendent Chain Functionalized Polyacetals That Display pH-Dependent Degradation: A Platform for the Development of Novel Polymer Therapeutics
R. Tomlinson (2002)
HOW TO OPTIMISE PEGVISOMANT TREATMENT OF ACROMEGALY SAFELY
A. Mukherjee (2002)
10.1016/S0927-7765(99)00064-8
Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials
V. Alakhov (1999)
10.1021/JA028100N
Designing macromolecules for therapeutic applications: polyester dendrimer-poly(ethylene oxide) "bow-tie" hybrids with tunable molecular weight and architecture.
E. Gillies (2002)
10.1177/096032719801700204
Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymerdoxorubicin (PK1)
R. Duncan (1998)
10.1002/MACP.1983.021841005
Polymers containing enzymatically degradable bonds, 7. Design of oligopeptide side-chains in poly[N-(2-hydroxypropyl)methacrylamide] copolymers to promote efficient degradation by lysosomal enzymes†
R. Duncan (1983)
10.1038/nrc900
Selective anticancer drugs
J. Atkins (2002)
10.1016/S0169-409X(02)00020-0
Introduction and overview of peptide and protein pegylation.
Veronese Fm (2002)



This paper is referenced by
10.1002/mabi.200800163
Poly(amidoamine) conjugates containing doxorubicin bound via an acid-sensitive linker.
Nathalie Lavignac (2009)
10.1201/B13159-5
Pegylated Zinc Protoporphyrin: A Micelle-Forming Polymeric Drug for Cancer Therapy
Jun Fang (2012)
10.1007/s10856-013-5034-y
Poly(2-oxazoline)s as materials for biomedical applications
Victor R de la Rosa (2013)
Development and application of flow experiments for quantitative studies on nanoparticle binding to biological surfaces
Ellen Broda (2016)
rug release characteristics of PAMAM dendrimer – drug conjugates with ifferent linkers
unus E. Kurtoglua (2009)
10.1080/10717540902757416
Biodegradable polymer films for releasing nanovehicles containing sirolimus
H. Kim (2009)
10.22028/D291-22721
Multilayer coating of gold nanoparticles (AuNP) with drug-polymer complex: Development and characterization
Nico Reum (2011)
10.1016/j.carbpol.2013.04.054
Synthesis and characterization of dextrin monosuccinate.
Xiuting Hu (2013)
10.1515/ntrev-2015-0057
Smart mesoporous silica nanoparticles for controlled-release drug delivery
Mahdi Karimi (2016)
10.1080/10611860600834011
pH-Responsive dendritic core-shell architectures as amphiphilic nanocarriers for polar drugs
Shangjie Xu (2006)
10.1002/MABI.200700066
Water-soluble pH-responsive dendritic core-shell nanocarriers for polar dyes based on poly(ethylene imine).
Shangjie Xu (2007)
10.1002/ANIE.200500519
Membrane-mimetic nanocarriers formed by a dipalmitoylated cell-penetrating peptide.
S. Keller (2005)
10.1080/10611860500065187
Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck
Anjan Nan (2005)
10.1016/S1359-6446(05)03384-2
Branching out into mix-and-match drug delivery.
J. Bradbury (2005)
Etude de l'interaction de dendrimères phosphorés avec les monocytes humains : recherche de récepteur (s)
Jérémy Le Dall (2015)
10.1002/POLA.23786
From Polymeric Particles to Multifunctional Nanocapsules for Biomedical Applications Using the Miniemulsion Process
K. Landfester (2010)
10.1016/j.drudis.2008.09.005
The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles?
L. Juillerat-Jeanneret (2008)
10.2174/156802608785848969
Preface. Polymer science and polymer therapeutics: macromolecules, dendrimers and nanomedicine.
M. Micha-Screttas (2008)
10.1016/J.MEE.2006.10.059
Nanotribology and nanomechanics of MEMS/NEMS and BioMEMS/BioNEMS materials and devices
B. Bhushan (2007)
10.1002/ANIE.200504599
Laser-induced release of encapsulated materials inside living cells.
A. Skirtach (2006)
10.1016/j.ymthe.2017.02.012
Deformable Discoidal Polymeric Nanoconstructs for the Precise Delivery of Therapeutic and Imaging Agents.
A. L. Palange (2017)
10.1039/B410943K
Biomedical applications of functionalised carbon nanotubes.
A. Bianco (2005)
10.1016/S1359-6446(04)03276-3
Dendrimers and dendritic polymers in drug delivery.
E. Gillies (2005)
10.1002/JPS.20096
Release from polymeric prodrugs: linkages and their degradation.
A. D'souza (2004)
10.1038/nbt995
Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation
S. Shaunak (2004)
SISTEM PENGHANTARAN OBAT TERTARGET, MACAM, JENIS-JENIS SISTEM PENGHANTARAN, DAN APLIKASINYA
L. Winarti (2015)
Synthesis, characterization and antiproliferative activities of novel modified poly (maleic anhydride-co-vinyl acetate)/cytosine β-D- arabinofuranoside hydrochloride conjugate
H. Bayram (2015)
10.1016/j.jconrel.2009.10.014
Size and shape effects in the biodistribution of intravascularly injected particles.
P. Decuzzi (2010)
10.1038/nmat2116
Biofunctional polymer nanoparticles for intra-articular targeting and retention in cartilage.
Dominique A. Rothenfluh (2008)
10.1021/bc900036f
Synthesis of linear polyether polyol derivatives as new materials for bioconjugation.
Z. Li (2009)
10.1002/ANGE.200802585
Nanomedizin – Herausforderung und Perspektiven
K. Riehemann (2009)
10.1007/978-981-15-5159-8
New Nanomaterials and Techniques for Tumor-targeted Systems
Rong-qin Huang (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar